Due to the high specificity of interleukin-13 receptor alpha 2 (IL13Rα2) for GBM with scarce expression in the surrounding normal brain tissue, IL13Ra2 was the first target of CAR-T cell therapy in GBM. Here, IL13RA2 is linked to glioblastoma.